Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
March 7, 2020
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
Justin Ferdinandus, John Violet, Shahneen Sandhu, et al.
Nuclear Medicine Communications
|
April 14, 2020
Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer-a prospective pilot study in an Asian population
Sue Ping Thang, Winnie Wing Chuen Lam, Aaron Kian Ti Tong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 7, 2018
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet, Price Jackson, Justin Ferdinandus, et al.
Journal of Nuclear Medicine Technology
|
June 5, 2024
Safety and Efficacy of <sup>90</sup>Y Selective Internal Radiation Therapy Using Glass Microspheres in Hepatocellular Carcinoma: A Southeast Asian Single-Institution Initial Experience
Cherie Wei Qi Ng, Muhammad Jai Bin Hassan, Charles Goh, et al.
Nuclear Medicine Communications
|
March 14, 2023
Optimization of Bayesian penalized likelihood reconstruction for 68 Ga-prostate-specific membrane antigen-11 PET/computed tomography
Charlene Yu Lin Tang, Gabriel K Y Lim, Wei Ming Chua, et al.
Asia-Pacific Journal of Clinical Oncology
|
June 2, 2026
The Present and Future of THERANOSTICS
Winnie Wing-Chuen Lam, Sue Ping Thang, Kelvin Siu-Hoong Loke, et al.
The Lancet. Oncology
|
May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S Hofman, John Violet, Rodney J Hicks, et al.
Asia-Pacific Journal of Clinical Oncology
|
March 31, 2023
Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study)
Wei Ming Chua, Winnie Wing-Chuen Lam, Aaron Kian-Ti Tong, et al.
European Urology
|
April 9, 2023
Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis
Kit Mun Chow, Wei Zheng So, Han Jie Lee, et al.
Asia-Pacific Journal of Clinical Oncology
|
May 29, 2025
Safety and Efficacy of Lutetium-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study)
Cherie Wei Qi Ng, Wei Ming Chua, Winnie Wing-Chuen Lam, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
European Journal of Nuclear Medicine and Molecular Imaging
|
March 7, 2020
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
Justin Ferdinandus, John Violet, Shahneen Sandhu, et al.
Nuclear Medicine Communications
|
April 14, 2020
Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer-a prospective pilot study in an Asian population
Sue Ping Thang, Winnie Wing Chuen Lam, Aaron Kian Ti Tong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 7, 2018
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet, Price Jackson, Justin Ferdinandus, et al.
Journal of Nuclear Medicine Technology
|
June 5, 2024
Safety and Efficacy of <sup>90</sup>Y Selective Internal Radiation Therapy Using Glass Microspheres in Hepatocellular Carcinoma: A Southeast Asian Single-Institution Initial Experience
Cherie Wei Qi Ng, Muhammad Jai Bin Hassan, Charles Goh, et al.
Nuclear Medicine Communications
|
March 14, 2023
Optimization of Bayesian penalized likelihood reconstruction for 68 Ga-prostate-specific membrane antigen-11 PET/computed tomography
Charlene Yu Lin Tang, Gabriel K Y Lim, Wei Ming Chua, et al.
Asia-Pacific Journal of Clinical Oncology
|
June 2, 2026
The Present and Future of THERANOSTICS
Winnie Wing-Chuen Lam, Sue Ping Thang, Kelvin Siu-Hoong Loke, et al.
The Lancet. Oncology
|
May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S Hofman, John Violet, Rodney J Hicks, et al.
Asia-Pacific Journal of Clinical Oncology
|
March 31, 2023
Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study)
Wei Ming Chua, Winnie Wing-Chuen Lam, Aaron Kian-Ti Tong, et al.
European Urology
|
April 9, 2023
Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis
Kit Mun Chow, Wei Zheng So, Han Jie Lee, et al.
Asia-Pacific Journal of Clinical Oncology
|
May 29, 2025
Safety and Efficacy of Lutetium-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study)
Cherie Wei Qi Ng, Wei Ming Chua, Winnie Wing-Chuen Lam, et al.
Page
of 3